HLA pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the Greater Middle East

Hend Chaker Masmoudi, Nariman Afify, Halima Alnaqbi, Zainab Alhalwachi, Guan K. Tay, Habiba Alsafar

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Specific HLA associations with drug hypersensitivity may vary between geographic regions and ethnic groups. There are little to no data related to HLA-drug hypersensitivity on populations who reside in the Greater Middle East (GME), a vast region spanning from Morocco in the west to Pakistan in the east. In this review, the authors intended to summarize the significant HLA alleles associated with hypersensitive drug reactions induced by different drugs, as have been found in different populations, and to summarize the prevalence of these alleles in the specific and diverse populations of the GME. For example, HLA-B*57:01 allele prevalence, associated with abacavir-induced hypersensitivity, ranges from 1% to 3%, and HLA-DPB1*03:01 prevalence, associated with aspirin-induced asthma, ranges from 10% to 14% in the GME population. Studying pharmacogenomic associations in the ethnic groups of the GME may allow the discovery of new associations, confirm ones found with a low evidence rate and enable cost-effectiveness analysis of allele screening before drug use.

Original languageBritish English
Pages (from-to)695-708
Number of pages14
JournalPharmacogenomics
Volume23
Issue number12
DOIs
StatePublished - 1 Aug 2022

Keywords

  • adverse drug reactions
  • drug hypersensitivity
  • Greater Middle East
  • HLA pharmacogenomic associations
  • HLA polymorphism

Fingerprint

Dive into the research topics of 'HLA pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the Greater Middle East'. Together they form a unique fingerprint.

Cite this